Alemtuzumab (Lemtrada®)

Assessment Status NCPE Assessment Process Complete
Drug Alemtuzumab
Brand Lemtrada®
Indication For adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features
Assessment Process
Rapid review commissioned 08/11/2013
Rapid review completed 02/12/2013
Rapid review outcome Full HTA Assessment Recommended
Full submission received from Applicant 28/01/2014
NCPE assessment completed 25/06/2014
NCPE assessment outcome The NCPE recommends reimbursement of alemtuzumab (Lemtrada®).